Tulin Morcol, PhD

President and Chief Scientific Officer

Dr. Morcol founded CaPtivate Pharmaceuticals (2011) at the research facilities of Pennsylvania Biotechnology Center incubator (PABC) as a spinoff from BioSante Pharmaceuticals Inc. Prior, she led the vaccine and drug formulation R&D activities at BioSante from 1998 until 2011 as the Director of Preclinical Development. She was one of the lead scientists who developed BioSante’s proprietary CaP nanoparticle (CaP) technology which was issued multiple US and fifteen foreign patents. She separately developed another novel process for large-scale GMP manufacturing of inorganic particles in the low nanometer to micrometer size ranges. Before moving to industry, she worked as a Research Faculty at Morehouse School of Medicine (Atlanta, GA) Department of Neurosciences for 4 years. Before coming to US, she worked as a Research Scientist at the Turkish Atomic Energy Agency for 5 years and received a research fellowship from the International Atomic Energy Agency (IAEA) to work at Hoffman La Roche (Basel,Switzerland). 

Tülin holds a PhD in Biochemical Engineering from Virginia Polytechnic Institute and State University (VA-Tech), MS and BS degrees in Chemical Engineering from Ankara University and Middle East Technical University (Turkey).

Nurgul Carkacı-Salli, PhD

Scientific Director, Molecular and Cellular Biology


Dr. Carkaci-Salli has recently joined CaPtivate Pharmaceuticals as the Scientific Director of Molecular and Cellular Biology. She has also been a Research Professor at the Pennsylvania State University (PSU), Hershey Medical Center, Department of Pharmacology, Hershey PA, since 2004.  Dr. Carkaci-Salli has over 20 years of experience in designing, managing, and conducting firsthand research projects in the field of molecular and cellular biology, performing high-throughput cellular assays, functional genomics, and biochemical analyses. She has extensive experience working with both stem cells (embryonic and tendon cells) and cancer cell lines, and mechanisms of chemoresistance in cancer cells. Her diverse experiences and skills in molecular, cellular, and biochemical techniques allows CaPtivate to expand its R&D and activities into new areas in drug delivery and bring new partnership and business opportunities.


Nurgül holds a Ph.D. and a MSSC in Phytopathology/Mycology from Ankara University, Turkey. She has done her postdoctoral studies at Oregon State University, Department of Botany and Plant Pathology.



Timothy M. Block, PhD

President and Co-Founder of the Hepatitis B Foundation, • Executive Chair of the Hepatitis B Foundation Board of Directors • Adjunct Professor at Geisinger Commonwealth School of Medicine and the University of Pennsylvania School of Medicine.


Dr. Block is also the founder and former president of the Pennsylvania Biotechnology Center incubator (PABC) and Baruch S. Blumberg Institute, which is the research arm of the Hepatitis B Foundation. He was named as “Visionary in Hepatitis” by the World Hepatitis Alliance in 2017. His work with Blumberg Institute and the PABC created the most successful life sciences incubators in the US. Dr Block is scientific co-founder of several life sciences companies, co-inventor on over 20 issued patents or patent applications, and authored/co-authored more than 290 scholarly papers. He was chosen to join the US National Academy of Inventors (2017). He, and his wife Joan, received the Distinguished Public Service Award (2020) from the American Association for the Study of Liver Diseases (AASLD).


Tim received his Ph.D. in Biochemistry from SUNY - Buffalo: Roswell Park Memorial Institute, Buffalo, NY. He later studied at the University of Oxford as a Sabbatical Fellow working with Dr. Baruch S. Blumberg (Nobel Laureate). During his studies at Oxford, he discovered a plant sugar that has now received the trade name “glycovir”.

Banu Onaral, PhD


H. H. Sun Professor Biomedical Engineering and Electrical Engineering, Senior Advisor to the President, Global Partnerships, School of Biomedical Engineering, Science & Health Systems, Drexel University, Philadelphia, PA; Founding director of the school from 1997 until 2014.


Dr Onaral’s research and academic focus is centered on information engineering, with special emphasis on complex systems, biomedical signal processing in ultrasound and optics, and functional optical brain imaging. Dr. Onaral's translational research efforts for rapid commercialization of biomedical technologies developed at Drexel and its partner institutions and created the Translational Research in Biomedical Technologies program. Dr. Onaral has founded several laboratories throughout her career; the most recent is the CONQUER (Cognitive Neuroengineering and Quantitative Experimental Research). CollabOrative, (established in 2008) is an interdisciplinary, multi-institutional, and international resource dedicated to the study of brain activation, development, and deployment of functional optical brain imaging technologies.


Banu holds a PhD in Biomedical Engineering from the University of Pennsylvania, a BSEE and a MSEE degrees in Electrical Engineering from Boğaziçi University, İstanbul, Turkey.

Sangeeta Underwood, Ph.D.


Senior Regulatory Affairs Manager/Consultant at LMI, Bioengineer IV (Senior Scientist and Project Management) at CBRN Medical (DoD), Fort Detrick, MD. Contractor, Venesco LLC.

Dr. Underwood has over 10 years of experience managing a diverse portfolio of projects and initiatives across multiple US Army Department of Defense (DoD) organizations, including Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasures, Medical Research Materiel Command (MRMC), and Defense Threat Reduction Agency (DTRA). She has proven expertise in reviewing, managing, and evaluating both early (research and development) and advanced development of vaccines and drugs, including FDA submissions of pre-IND and IND packages for drug/vaccine products and medical/diagnostic devices. At her current position at LMI, she oversees transfer of technology and products and leads communications with stakeholders and contractors.


Sangeeta received her Ph.D. in Biology & Microbiology/infectious diseases from the Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), India.

Anthony Hickey, PhD, DSc

Emeritus Professor, University of North Carolina, School of Medicine and Eshelman School of Pharmacy at the University of North Carolina (UNC) at Chapel Hill • Distinguished Fellow and Program Director in inhaled therapeutics in the Center for Engineered Systems at RTI International, Research Triangle Park, NC • Adjunct Professor of Biomedical Engineering at the UNC School of Medicine at Chapell Hill.


Anthony Hickey has been the founder and the current Chief Executive Officer of Astartein LLC since 2013. He also serves as the Chief Scientific Officer for TFF Pharmaceuticals. Dr. Hickey was also the founder of three other pharmaceutical companies; Cirrus Pharmaceuticals Inc. (1997) which was acquired by Kemwell in 2013, Oriel Therapeutics Inc. (2001), which was acquired by Sandoz in 2010. Dr. Hickey received the David W Grant Award in Physical Pharmacy of the American Association of Pharmaceutical Scientists (2015); Thomas T Mercer Joint Prize for Excellence in Inhaled Medicines and Pharmaceutical Aerosols of the American Association for Aerosol Research and the International Society for Aerosols in Medicine (2017), and the Ralph Shangraw Memorial Award for Excipient and Excipient Technology of the International Pharmaceutical Excipient Consortium Foundation (2018). He has edited/authored nine texts on pharmaceutical inhalation aerosols and coauthored seven others on pharmaceutical process engineering, particulate science, and tuberculosis therapy.


Dr. Hickey holds a Ph.D. in Pharmaceutical Sciences from Aston University in Birmingham, UK.